Viral and non-viral vector platform evolution

CELL AND GENE THERAPY INSIGHTS

June 2024

Viral and non-viral vector platform evolution

Download PDF

Foreword

Viral and non-viral vector platform evolution

Viral and non-viral vector platform evolution

Review

Switching from ex vivo to in vivo: approaches and considerations for generating cell therapies directly in the patient upon in vivo gene delivery

Switching from ex vivo to in vivo: approaches and considerations for generating cell therapies directly in the patient upon in vivo gene delivery

Self-replicating RNA for mRNA vaccine development

Self-replicating RNA for mRNA vaccine development

Kenneth Lundstrom

Innovator Insight

It’s a match: cell line engineering for AAV manufacturing expands the options for therapeutic programs

It’s a match: cell line engineering for AAV manufacturing expands the options for therapeutic programs

Commentary

What are the issues associated with developing gene therapies for rare disease and are the current development models working?

What are the issues associated with developing gene therapies for rare disease and are the current development models working?

Samir Nuseibeh, Els Henckaerts

FastFacts

Get your non-viral T cell engineering process ready for clinical manufacturing

Get your non-viral T cell engineering process ready for clinical manufacturing

Melanie Rietenbach

Viewpoint

Expanding the therapeutic index of lipid nanoparticles: potential key for clinical translation success

Expanding the therapeutic index of lipid nanoparticles: potential key for clinical translation success

Interview

Developing focused ultrasound as a novel gene delivery tool to overcome the blood–brain barrier

Developing focused ultrasound as a novel gene delivery tool to overcome the blood–brain barrier

Rikke Hahn Kofoed

Advancing capsid engineering: improving tropism and delivery efficiency of AAV

Advancing capsid engineering: improving tropism and delivery efficiency of AAV